FBXO15

Summary

FBXO15 (F-box protein 15, HGNC:13617) is a protein-coding gene on chromosome 18q22.3, encoding F-box only protein 15 (Q8NCQ5). Substrate-recognition component of the SCF (SKP1-CUL1-F-box protein)-type E3 ubiquitin ligase complex.

Members of the F-box protein family, such as FBXO15, are characterized by an approximately 40-amino acid F-box motif. SCF complexes, formed by SKP1 (MIM 601434), cullin (see CUL1; MIM 603134), and F-box proteins, act as protein-ubiquitin ligases. F-box proteins interact with SKP1 through the F box, and they interact with ubiquitination targets through other protein interaction domains (Jin et al., 2004 [PubMed 15520277]).

Source: NCBI Gene 201456 — RefSeq curated summary.

At a glance

• Gene–disease (curated): Tourette syndrome (No Known Disease Relationship, GenCC)
• GWAS associations: 13
• Clinical variants (ClinVar): 89 total — 1 pathogenic
• MANE Select transcript: NM_001142958

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13617
Approved symbol	FBXO15
Name	F-box protein 15
Location	18q22.3
Locus type	gene with protein product
Status	Approved
Aliases	MGC39671, FBX15
Ensembl gene	ENSG00000141665
Ensembl biotype	protein_coding
OMIM	609093
Entrez	201456

Gene structure

Transcript identifiers

Ensembl transcripts: 17 — 7 protein_coding, 6 nonsense_mediated_decay, 3 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000419743, ENST00000577575, ENST00000578399, ENST00000579108, ENST00000579517, ENST00000580088, ENST00000580552, ENST00000580806, ENST00000581214, ENST00000582526, ENST00000583443, ENST00000584425, ENST00000585174, ENST00000648529, ENST00000879153, ENST00000879154, ENST00000879155

RefSeq mRNA: 2 — MANE Select: NM_001142958 NM_001142958, NM_152676

CCDS: CCDS45884

Canonical transcript exons

ENST00000419743 — 10 exons

Exon	Start	End
ENSE00001620471	74147670	74147834
ENSE00002733826	74073368	74073730
ENSE00003463973	74140202	74140312
ENSE00003474091	74125975	74126101
ENSE00003487774	74130416	74130658
ENSE00003530535	74081927	74082051
ENSE00003534536	74123368	74123510
ENSE00003550765	74135762	74135866
ENSE00003560171	74129405	74129614
ENSE00003666660	74124489	74124571

Expression profiles

Bgee: expression breadth ubiquitous, 197 present calls, max score 98.03.

FANTOM5 (CAGE): breadth broad, TPM avg 1.1347 / max 39.2444, expressed in 485 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
172417	0.5787	296
172416	0.4767	251
172415	0.0792	36

Top tissues by expression

249 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
bronchial epithelial cell	CL:0002328	98.03	gold quality
bronchus	UBERON:0002185	96.75	gold quality
right uterine tube	UBERON:0001302	93.03	gold quality
mucosa of paranasal sinus	UBERON:0005030	91.32	gold quality
oocyte	CL:0000023	90.76	gold quality
right testis	UBERON:0004534	89.82	gold quality
left testis	UBERON:0004533	89.58	gold quality
testis	UBERON:0000473	88.14	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	88.11	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	88.10	gold quality
sperm	CL:0000019	87.59	gold quality
secondary oocyte	CL:0000655	86.85	gold quality
caput epididymis	UBERON:0004358	85.57	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	85.55	gold quality
epithelium of nasopharynx	UBERON:0001951	85.55	gold quality
adult organism	UBERON:0007023	81.55	gold quality
oviduct epithelium	UBERON:0004804	79.76	gold quality
pituitary gland	UBERON:0000007	78.25	gold quality
caudate nucleus	UBERON:0001873	77.90	gold quality
fallopian tube	UBERON:0003889	77.89	gold quality
Brodmann (1909) area 23	UBERON:0013554	77.86	gold quality
adenohypophysis	UBERON:0002196	77.42	gold quality
hypothalamus	UBERON:0001898	77.09	gold quality
kidney epithelium	UBERON:0004819	76.54	silver quality
putamen	UBERON:0001874	76.28	gold quality
middle temporal gyrus	UBERON:0002771	76.24	gold quality
nasal cavity epithelium	UBERON:0005384	76.09	gold quality
nucleus accumbens	UBERON:0001882	75.97	gold quality
corpus callosum	UBERON:0002336	75.17	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	74.75	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-6678	yes	1231.97
E-ANND-3	yes	6.38
E-GEOD-109979	no	84.11

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): POU5F1, UTF1

miRNA regulators (miRDB)

8 targeting FBXO15, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-1305	99.91	71.43	3443
HSA-MIR-3529-3P	99.90	73.55	3045
HSA-MIR-6885-3P	99.75	70.36	3187
HSA-MIR-3158-5P	99.65	67.51	1763
HSA-MIR-4676-5P	97.54	65.29	715
HSA-MIR-575	97.54	65.18	718

Literature-anchored findings (GeneRIF, showing 2)

• These data suggest that FBXO15 and Ube2r1 regulate P-gp expression through the ubiquitin-proteasome pathway. (PMID:23465077)
• FBXO15 plays a critical suppressive functional role in regulation of breast cancer progression. (PMID:34083507)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	fbxo15	ENSDARG00000016897
danio_rerio	zgc:161973	ENSDARG00000029848
mus_musculus	Fbxo15	ENSMUSG00000034391
rattus_norvegicus	Fbxo15	ENSRNOG00000038225

Paralogs (1): FBXW5 (ENSG00000159069)

Protein

Protein identifiers

F-box only protein 15 — Q8NCQ5 (reviewed: Q8NCQ5)

All UniProt accessions (10): A0A3B3IRP1, Q8NCQ5, J3KRQ6, J3KRS5, J3KRT3, J3KS84, J3QKV0, J3QL50, J3QLF9, J3QRE7

UniProt curated annotations — full annotation on UniProt →

Function. Substrate-recognition component of the SCF (SKP1-CUL1-F-box protein)-type E3 ubiquitin ligase complex.

Subunit / interactions. Directly interacts with SKP1 and CUL1.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8NCQ5-1	1	yes
Q8NCQ5-2	2

RefSeq proteins (2): NP_001136430, NP_689889 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001810	F-box_dom	Domain
IPR036047	F-box-like_dom_sf	Homologous_superfamily

Pfam: PF12937

UniProt features (4 total): chain 1, domain 1, splice variant 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8NCQ5-F1	77.42	0.38

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-8951664	Neddylation
R-HSA-983168	Antigen processing: Ubiquitination & Proteasome degradation

MSigDB gene sets: 107 (showing top): REACTOME_ADAPTIVE_IMMUNE_SYSTEM, REACTOME_CLASS_I_MHC_MEDIATED_ANTIGEN_PROCESSING_PRESENTATION, REACTOME_ANTIGEN_PROCESSING_UBIQUITINATION_PROTEASOME_DEGRADATION, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, SENGUPTA_NASOPHARYNGEAL_CARCINOMA_DN, WCTCNATGGY_UNKNOWN, chr18q22, GOBP_SCF_DEPENDENT_PROTEASOMAL_UBIQUITIN_DEPENDENT_PROTEIN_CATABOLIC_PROCESS, GOBP_PROTEASOMAL_PROTEIN_CATABOLIC_PROCESS, GOBP_PROTEIN_CATABOLIC_PROCESS, GOCC_SCF_UBIQUITIN_LIGASE_COMPLEX, GOCC_TRANSFERASE_COMPLEX, GOBP_PROTEOLYSIS, GOCC_CULLIN_RING_UBIQUITIN_LIGASE_COMPLEX, GOCC_UBIQUITIN_LIGASE_COMPLEX

GO Biological Process (0):

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (2): cytosol (GO:0005829), SCF ubiquitin ligase complex (GO:0019005)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Post-translational protein modification	1
Class I MHC mediated antigen processing & presentation	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	1
cytoplasm	1
cellular anatomical structure	1
cullin-RING ubiquitin ligase complex	1

Protein interactions and networks

STRING

816 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FBXO15	NANOG	Q9H9S0	849
FBXO15	KLF4	P78338	844
FBXO15	POU5F1	P31359	827
FBXO15	SOX2	P48431	819
FBXO15	LIN28A	Q9H9Z2	800
FBXO15	PRDM14	Q9GZV8	643
FBXO15	MYC	P01106	637
FBXO15	UTF1	Q5T230	624
FBXO15	NR0B1	P51843	601
FBXO15	ZFP42	Q96MM3	585
FBXO15	ESRRB	O95718	575
FBXO15	TBX3	O15119	569
FBXO15	SKP1	P34991	561
FBXO15	SOX1	O00570	555
FBXO15	CUL1	Q13616	540

IntAct

9 interactions, top by confidence:

A	B	Type	Score
FBXO15	JPH3	psi-mi:“MI:0915”(physical association)	0.560
FBXO15	CPA6	psi-mi:“MI:0914”(association)	0.530
FBXO15	SRPK1	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
FBXO15	DARS2	psi-mi:“MI:0915”(physical association)	0.400
FBXO15	GAPDHS	psi-mi:“MI:0915”(physical association)	0.400
FBXO15	HSPD1	psi-mi:“MI:0914”(association)	0.350

BioGRID (21): OS9 (Affinity Capture-MS), HINT3 (Affinity Capture-MS), CPA6 (Affinity Capture-MS), CPA6 (Affinity Capture-MS), HINT3 (Affinity Capture-MS), HSPD1 (Affinity Capture-MS), SKP1 (Affinity Capture-Western), SKP1 (Affinity Capture-Western), FBXO15 (Proximity Label-MS), HINT3 (Affinity Capture-MS), CPA6 (Affinity Capture-MS), GAPDHS (Affinity Capture-MS), FBXO15 (Cross-Linking-MS (XL-MS)), FBXO15 (Affinity Capture-MS), FBXO15 (Affinity Capture-Western)

ESM2 similar proteins: A4D1B5, D3IUT5, O43149, O88480, Q15345, Q1AE95, Q28HN9, Q29RR1, Q3SYW0, Q3TCV3, Q3U1D0, Q3U6Q4, Q3UHA3, Q571B6, Q5EA86, Q5M9H1, Q5PNP6, Q5R8D5, Q5R9H2, Q5SSH7, Q5SW28, Q5TIA1, Q5ZIB8, Q68FS7, Q6DRL4, Q6INI0, Q6TNU3, Q7Z2Z1, Q7Z4M0, Q80VA5, Q8BMG1, Q8BQ33, Q8C7B8, Q8IXX5, Q8K1C9, Q8NCQ5, Q8ND61, Q8TF30, Q8WXE1, Q920I9

Diamond homologs: C5FP68, Q3SYW0, Q7TPD1, Q7TSL3, Q86XK2, Q8NCQ5, Q9GKV7, Q9QZN0, A2VE78, B9G2A8, Q09855, Q29L39, Q54QG5, Q5BJ29, Q5R6E1, Q5XGI3, Q8C2S5, Q94251, Q9SRU2, Q9UJT9, Q9UKA1, Q9VLT5

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
FBXO15	“down-regulates quantity by destabilization”	CRLS1	binding
FBXO15	“up-regulates activity”	“Cullin 1-RBX1-Skp1”	binding
“Cullin 1-RBX1-Skp1”	“down-regulates quantity by destabilization”	FBXO15	polyubiquitination

Disease & clinical

Clinical variants and AI predictions

ClinVar

89 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	75
Likely benign	6
Benign	1

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
1807707	GRCh37/hg19 18q21.33-23(chr18:61520071-78014123)x1	Pathogenic

SpliceAI

2291 predictions. Top by Δscore:

Variant	Effect	Δscore
18:74073726:CAACT:C	acceptor_gain	1.0000
18:74073727:AACT:A	acceptor_gain	1.0000
18:74073727:AACTC:A	acceptor_loss	1.0000
18:74073728:ACTC:A	acceptor_loss	1.0000
18:74073729:CT:C	acceptor_gain	1.0000
18:74073730:TC:T	acceptor_loss	1.0000
18:74073731:C:CA	acceptor_loss	1.0000
18:74073731:C:CC	acceptor_gain	1.0000
18:74073732:T:A	acceptor_loss	1.0000
18:74123397:C:CT	donor_gain	1.0000
18:74123507:GGGG:G	acceptor_gain	1.0000
18:74123511:C:CC	acceptor_gain	1.0000
18:74124487:A:AC	donor_gain	1.0000
18:74124488:C:CC	donor_gain	1.0000
18:74126113:A:C	acceptor_gain	1.0000
18:74126117:C:CT	acceptor_gain	1.0000
18:74126118:A:T	acceptor_gain	1.0000
18:74135757:CTT:C	donor_loss	1.0000
18:74135758:TTA:T	donor_loss	1.0000
18:74135759:TAC:T	donor_loss	1.0000
18:74135760:A:AC	donor_gain	1.0000
18:74135760:A:C	donor_loss	1.0000
18:74135761:C:CT	donor_gain	1.0000
18:74135761:CTTGT:C	donor_gain	1.0000
18:74135862:GCATT:G	acceptor_gain	1.0000
18:74135863:CATT:C	acceptor_gain	1.0000
18:74135863:CATTC:C	acceptor_gain	1.0000
18:74135865:TT:T	acceptor_gain	1.0000
18:74135865:TTC:T	acceptor_loss	1.0000
18:74135867:C:CA	acceptor_loss	1.0000

AlphaMissense

3335 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
18:74081959:A:G	W411R	0.991
18:74081959:A:T	W411R	0.991
18:74073668:A:C	S442R	0.990
18:74073668:A:T	S442R	0.990
18:74073670:T:G	S442R	0.990
18:74129598:A:G	W198R	0.989
18:74129598:A:T	W198R	0.989
18:74123439:A:G	L356P	0.986
18:74129508:A:G	W228R	0.985
18:74129508:A:T	W228R	0.985
18:74073476:A:C	F506L	0.984
18:74073476:A:T	F506L	0.984
18:74073478:A:G	F506L	0.984
18:74124509:G:C	S325R	0.980
18:74124509:G:T	S325R	0.980
18:74124511:T:G	S325R	0.980
18:74124551:A:C	F311L	0.980
18:74124551:A:T	F311L	0.980
18:74124553:A:G	F311L	0.980
18:74124549:A:T	V312D	0.979
18:74073516:A:G	L493P	0.978
18:74073679:A:G	W439R	0.978
18:74073679:A:T	W439R	0.978
18:74073705:A:G	L430P	0.978
18:74130651:A:G	W114R	0.977
18:74130651:A:T	W114R	0.977
18:74123439:A:T	L356H	0.974
18:74125985:C:T	G301E	0.974
18:74073577:C:G	G473R	0.973
18:74073577:C:T	G473R	0.973

dbSNP variants (sampled 300 via entrez): RS1000085878 (18:74075014 G>C,T), RS1000093293 (18:74116499 A>T), RS1000194548 (18:74147177 C>G), RS1000227084 (18:74147932 C>G,T), RS1000229859 (18:74136177 A>G), RS1000244887 (18:74109550 T>C,G), RS1000345604 (18:74102966 G>A), RS1000355217 (18:74142839 C>T), RS1000391757 (18:74099052 GAGGTAA>G), RS1000462557 (18:74117748 G>A), RS1000474573 (18:74147923 A>C,G,T), RS1000509878 (18:74137750 G>A), RS1000541290 (18:74075194 C>T), RS1000602226 (18:74088184 T>C), RS1000640517 (18:74144006 C>T)

Disease associations

OMIM: gene MIM:609093 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
Tourette syndrome	No Known Disease Relationship	Unknown

Mondo (1): Tourette syndrome (MONDO:0007661)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

13 associations (top):

Study	Trait	p-value
GCST001856_49	Thyroid hormone levels	3.000000e-08
GCST002053_7	Sleep duration	5.000000e-06
GCST002097_46	Coronary artery calcification	6.000000e-06
GCST002308_8	Mean arterial pressure (alcohol consumption interaction)	8.000000e-07
GCST002309_4	Diastolic blood pressure (alcohol consumption interaction)	6.000000e-07
GCST002337_166	Amyotrophic lateral sclerosis (sporadic)	2.000000e-07
GCST002361_10	Smooth-surface caries	3.000000e-06
GCST004833_8	Cervical cancer	2.000000e-06
GCST009391_1733	Metabolite levels	9.000000e-06
GCST009391_1936	Metabolite levels	3.000000e-06
GCST009391_2095	Metabolite levels	8.000000e-06
GCST012034_10	Sleep (1/2-day periodicity)	4.000000e-10
GCST012419_3	Longevity (100 years and older)	3.000000e-09

EFO canonical traits (8, from GWAS)

EFO ID	Trait name
EFO:0004730	hormone measurement
EFO:0004723	coronary artery calcification
EFO:0004329	alcohol drinking
EFO:0006340	mean arterial pressure
EFO:0006336	diastolic blood pressure
EFO:0010375	phosphatidylcholine 34:1 measurement
EFO:0009766	asparagine measurement
EFO:0010373	phosphatidylcholine 32:1 measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D005879	Tourette Syndrome	C10.228.140.079.898; C10.228.662.825.800; C10.574.500.850; C16.320.400.820; F03.625.992.850

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

25 total (human), top 25 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Air Pollutants	decreases expression, increases abundance, increases expression	2
Aflatoxin B1	decreases expression, decreases methylation	2
methylmercuric chloride	decreases expression	1
methyleugenol	decreases expression	1
titanium dioxide	decreases expression	1
ochratoxin A	increases expression	1
CGP 52608	affects binding, increases reaction	1
abrine	decreases expression	1
bisphenol S	increases methylation	1
jinfukang	increases expression	1
Rosiglitazone	increases expression	1
Sunitinib	increases expression	1
Cadmium	increases abundance, increases ubiquitination	1
Dichlorodiphenyl Dichloroethylene	decreases expression	1
N-Nitrosopyrrolidine	decreases expression	1
Silicon Dioxide	decreases expression	1
Smoke	increases abundance, increases expression	1
Tobacco Smoke Pollution	decreases expression	1
Tretinoin	decreases expression	1
Valproic Acid	decreases methylation	1
Cyclosporine	decreases expression	1
Cadmium Chloride	increases abundance, increases ubiquitination	1
Okadaic Acid	decreases expression	1
Particulate Matter	decreases expression, increases abundance	1
Magnetite Nanoparticles	decreases expression	1

Cellosaurus cell lines

3 cell lines: 3 embryonic stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A1Q8	SEES3-1V human FBXO15, clone1	Embryonic stem cell	Male
CVCL_A1Q9	SEES3-1V human FBXO15, clone2	Embryonic stem cell	Male
CVCL_A1R0	SEES3-1V human FBXO15, clone3	Embryonic stem cell	Male

Clinical trials (associated diseases)

183 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00152750	PHASE4	UNKNOWN	Study of Clonidine on Sleep Architecture in Children With Tourette’s Syndrome (TS) and Comorbid ADHD
NCT00226824	PHASE4	TERMINATED	Safety Study of Galantamine in Tic Disorders
NCT00241176	PHASE4	COMPLETED	Open Label Trial of Aripiprazole in Children and Adolescents With Tourette’s Disorder
NCT00370838	PHASE4	COMPLETED	Comparison of Keppra and Clonidine in the Treatment of Tics
NCT01018056	PHASE4	COMPLETED	Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission
NCT01547000	PHASE4	COMPLETED	Guanfacine in Children With Tic Disorders
NCT03239210	PHASE4	COMPLETED	Effects of Ondansetron in Obsessive-compulsive and Tic Disorders
NCT00004376	PHASE3	COMPLETED	Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder
NCT00206323	PHASE3	COMPLETED	A Randomized, Placebo-controlled, Tourette Syndrome Study.
NCT00206336	PHASE3	COMPLETED	An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome.
NCT00478842	PHASE3	COMPLETED	Pallidal Stimulation and Gilles de la Tourette Syndrome
NCT00681863	PHASE3	TERMINATED	Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome
NCT01501695	PHASE3	COMPLETED	Phase III Study of 5LGr to Treat Tic Disorder
NCT03087201	PHASE3	COMPLETED	CANNAbinoids in the Treatment of TICS (CANNA-TICS)
NCT03487783	PHASE3	COMPLETED	Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Tourette’s Syndrome
NCT03567291	PHASE3	TERMINATED	Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents
NCT03571256	PHASE3	COMPLETED	A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)
NCT06021522	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette’s Disorder
NCT00004393	PHASE2	COMPLETED	Phase II Double Blind Placebo Controlled Trial of Risperidone in Tourette Syndrome
NCT00004652	PHASE2	COMPLETED	Phase II Pilot Controlled Study of Short Vs Longer Term Pimozide (Orap) Therapy in Tourette Syndrome
NCT00231985	PHASE2	COMPLETED	Effectiveness of Behavior Therapy and Psychosocial Therapy for the Treatment of Tourette Syndrome and Chronic Tic Disorder
NCT00311909	PHASE2	COMPLETED	Thalamic Deep Brain Stimulation for Tourette Syndrome
NCT00529308	PHASE2	COMPLETED	Transcranial Magnetic Stimulation (TMS) for Individuals With Tourette’s Syndrome
NCT00558467	PHASE2	COMPLETED	Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria
NCT01043549	PHASE2	TERMINATED	Repetitive Transcranial Magnetic Stimulation of the Posterior Parietal Cortex in Patients Suffering From Gilles de la Tourette Syndrome
NCT01133353	PHASE2	WITHDRAWN	A Study of the Effectiveness and Safety of Tetrabenazine MR in Pediatric Subjects With Tourette’s Syndrome
NCT01475383	PHASE2	WITHDRAWN	Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette’s Syndrome
NCT01647269	PHASE2	COMPLETED	A Trial of Bilateral Deep Brain Stimulation to the Globus Pallidus Internum in Tourette Syndrome
NCT01904773	PHASE2	COMPLETED	Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette’s Disorder
NCT02102698	PHASE2	COMPLETED	Ecopipam Treatment of Tourette’s Syndrome in Subjects 7-17 Years
NCT02217007	PHASE2	WITHDRAWN	A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome
NCT02247206	PHASE2	COMPLETED	VoIP Delivered Behavior Therapy for Tourette Syndrome
NCT02581865	PHASE2	COMPLETED	Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome
NCT02619084	PHASE2	COMPLETED	Subthalamic Stimulation in Tourette’s Syndrome
NCT02679079	PHASE2	COMPLETED	Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome
NCT02879578	PHASE2	COMPLETED	Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome
NCT03066193	PHASE2	COMPLETED	Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome
NCT03247244	PHASE2	TERMINATED	Safety and Efficacy of Cannabis in Tourette Syndrome
NCT03325010	PHASE2	COMPLETED	Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
NCT03444038	PHASE2	COMPLETED	Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome